title: Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy.
abstract: The prevalence of osteoporosis in men with prostate cancer (PCa) on androgen deprivation therapy (ADT) is well documented, with up to 53% affected by this bone condition. However, there has been less emphasis on the burden of severe bone loss in men with PCa but not undergoing ADT. Therefore, the purpose of this meta-analysis is to compile evidence from the literature on the bone health of hormone-naïve PCa patients and to compare it to the bone health of men with PCa on ADT. Three databases were searched for the relevant literature published from 1990 until January 2014. The pooled prevalence of osteoporosis, low bone mass, and normal bone mass were estimated for this patient group and compared with similar subgroups from a previously published meta-analysis. The prevalence of osteoporosis varies from 4 to 38% in hormone-naïve PCa patients, and men with more advanced disease have a higher prevalence of osteoporosis. Men with PCa on ADT have poorer bone health than their hormone-naïve counterparts, but the trend toward poorer bone health with metastatic disease remains. In conclusion, it was found that men with PCa experience poor bone health prior to treatment with ADT. These results suggest that all men with PCa should have regular bone health monitoring, whether they commence ADT or not, in order to prevent or indeed minimize the morbidity that accompanies osteoporosis.
authors: Centre for Dietetics Research (C-DIET-R), School of Human Movement and Nutrition Science, The University of Queensland, St Lucia, QLD, 4072, Australia. a.lassemillante@uq.edu.au.|Mater Research Institute, University of Queensland, Kent Street, Woolloongabba, QLD, 4102, Australia. a.lassemillante@uq.edu.au.
authors: Annie-Claude M
authors: AC
authors: Lassemillante
authors: Clinical Epidemiology Unit, School of Population Health, The University of Queensland, Herston, QLD, 4006, Australia.
authors: Suhail A R
authors: SA
authors: Doi
authors: Mater Research Institute, University of Queensland, Kent Street, Woolloongabba, QLD, 4102, Australia.
authors: John D
authors: JD
authors: Hooper
authors: Mater Research Institute, University of Queensland, Kent Street, Woolloongabba, QLD, 4102, Australia.|The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, QLD, 4102, Australia.
authors: John B
authors: JB
authors: Prins
authors: Centre for Dietetics Research (C-DIET-R), School of Human Movement and Nutrition Science, The University of Queensland, St Lucia, QLD, 4072, Australia.|Mater Research Institute, University of Queensland, Kent Street, Woolloongabba, QLD, 4102, Australia.
authors: Olivia R L
authors: OR
authors: Wright
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced / Q000453:epidemiology* / Q000209:etiology; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D000726:Androgen Antagonists
keywords: Androgen deprivation therapy; Bone health; Meta-analysis; Osteopenia; Osteoporosis; Prostate cancer
references: Br J Urol. 1985 Dec;57(6):721-3
references: 4084733
references: Urology. 2003 Feb;61(2 Suppl 1):32-8
references: 12667885
references: BJU Int. 2009 Mar;103(6):753-7
references: 19007370
references: J Clin Epidemiol. 2012 Sep;65(9):934-9
references: 22742910
references: Stat Med. 2001 Mar 30;20(6):825-40
references: 11252006
references: J Urol. 2002 Jun;167(6):2361-7; discussion 2367
references: 11992038
references: Urology. 2007 Mar;69(3):500-4
references: 17382153
references: Cancer. 2013 Feb 15;119(4):863-70
references: 23065626
references: Osteoporos Int. 2008 Apr;19(4):385-97
references: 18292978
references: Endocr Relat Cancer. 2008 Dec;15(4):943-52
references: 18667685
references: Nat Rev Rheumatol. 2012 Nov;8(11):674-83
references: 23045255
references: J Clin Epidemiol. 2009 Oct;62(10):1006-12
references: 19631508
references: Cancer. 2004 Mar 1;100(5):892-9
references: 14983482
references: Contemp Clin Trials. 2011 Mar;32(2):288-98
references: 21147265
references: Bone. 2009 May;44(5):734-43
references: 19195497
references: Osteoporos Int. 2013 Oct;24(10):2571-9
references: 23563932
references: J Clin Endocrinol Metab. 2005 Dec;90(12):6410-7
references: 16189261
references: J Clin Epidemiol. 2014 Aug;67(8):897-903
references: 24794697
references: Endocrine. 2014 Apr;45(3):370-81
references: 24174178
references: Bone. 2008 Dec;43(6):1115-21
references: 18793764
references: J Urol. 2010 Jun;183(6):2200-5
references: 20399451
references: J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
references: 21646368
references: Asian J Androl. 2004 Mar;6(1):75-7
references: 15064839
references: Urology. 1999 Oct;54(4):607-11
references: 10510915
references: J Bone Miner Res. 1994 Aug;9(8):1137-41
references: 7976495
references: BJU Int. 2015 Apr;115 Suppl 5:3-13
references: 25327530
references: BJU Int. 2003 Nov;92(7):690-4
references: 14616447
references: J Bone Miner Res. 2000 Feb;15(2):322-31
references: 10703935
references: J Urol. 2002 Jun;167(6):2448-52
references: 11992055
references: JAMA. 2012 Jan 18;307(3):255-6
references: 22253389
references: Clin Genitourin Cancer. 2013 Mar;11(1):33-8
references: 23000203
references: Nat Rev Cancer. 2005 Jan;5(1):21-8
references: 15630412
references: Cancer. 2009 Jun 1;115(11):2388-99
references: 19399748
references: Stat Med. 2011 Dec 10;30(28):3304-12
references: 21964669
references: Osteoporos Int. 2010 Apr;21(4):647-53
references: 19533207
references: J Clin Endocrinol Metab. 2011 Jan;96(1):53-8
references: 21118827
references: Epidemiology. 2008 Jan;19(1):94-100
references: 18090860
references: Endocr Rev. 1998 Feb;19(1):18-54
references: 9494779
references: J Bone Miner Res. 1997 Nov;12 (11):1761-8
references: 9383679
references: J Clin Endocrinol Metab. 2001 Sep;86(9):4133-8
references: 11549639
references: J Clin Oncol. 2012 May 20;30(15):1864-70
references: 22493411
references: BJU Int. 2007 Apr;99(4):812-5; discussion 815-6
references: 17378843
references: J Clin Nurs. 2007 Apr;16(4):734-41
references: 17402955
references: Qual Health Res. 2009 Apr;19(4):432-43
references: 19229061
references: Eur J Surg Oncol. 1987 Feb;13(1):41-9
references: 3102281
references: N Engl J Med. 2005 Jan 13;352(2):154-64
references: 15647578
references: Urology. 2004 Aug;64(2):335-40
references: 15302490
references: Osteoporos Int. 2012 Apr;23(4):1437-44
references: 21755400
references: Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):415-8
references: 21382981
references: Andrology. 2013 Jul;1(4):583-9
references: 23686896
references: Med J Aust. 2011 Mar 21;194(6):301-6
references: 21426285
references: Cancer. 2001 Jun 15;91(12):2238-45
references: 11413511
references: Nat Rev Cancer. 2011 Jun;11(6):411-25
references: 21593787
references: Radiother Oncol. 2009 Nov;93(2):153-67
references: 19765845
references: Cancer. 2001 May 15;91(10):1889-95
references: 11346871
references: Br J Cancer. 2000 Feb;82(4):858-64
references: 10732759